BIOS Capital Management, LP

In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 12, 2025), BIOS Capital Management, LP reported 6 stock positions worth $72.6 million. Its top holding was Actuate Therapeutics (ACTU) at 83.9% of the portfolio, followed by Opus Genetics (IRD, 4.8%) and Lantern Pharma (LTRN, 4.7%). Compared with Q1 2025, it added to 2 and reduced 2. The biggest buy was Opus Genetics (IRD, shares +270%) and the biggest sale IN8BIO (INAB, shares −97%).

Most Recent 13F
Q2 2026
Location
Fort Worth, TX
CIK
0001813845
Portfolio Value
$72.6M (Q2 2025)
SEC Filing
0001104659-25-076893 ↗ filed Aug 12, 2025

Holdings Value

0$20.0M$40.0M$60.0M$80.0M$100.0M Q4 2024: $94.1M Q4 2024 Q1 2025: $79.2M Q1 2025 Q2 2025: $72.6M $72.6M Q2 2025 Q3 2025: $88.9M Q3 2025 Q4 2025: $82.6M Q4 2025 Q1 2026: $52.9M Q1 2026 Q2 2026: $41.7M Q2 2026

Holdings 6 stocks · $72.6M
ACTU Actuate Therapeutics Inc. 83.89% 9,965,079 $60.9M Add +0.7%
IRD Opus Genetics Inc. 4.77% 3,683,429 $3.5M Add +270.1%
LTRN Lantern Pharma Inc. 4.68% 1,075,952 $3.4M Reduce -10.9%
RNTX Rein Therapeutics Inc. 3.26% 1,690,751 $2.4M No change
CGTX Cognition Therapeutics Inc. 2.56% 6,000,000 $1.9M No change
INAB IN8BIO Inc. 0.83% 286,664 $599K Reduce -96.7%

Portfolio Sells Q1 2025 → Q2 2025
INAB IN8BIO Inc. Reduce -96.7% 0.83% −0.98
LTRN Lantern Pharma Inc. Reduce -10.9% 4.68% −0.71

Portfolio Buys Q1 2025 → Q2 2025
IRD Opus Genetics Inc. Add +270.1% 4.77% +3.54
ACTU Actuate Therapeutics Inc. Add +0.7% 83.89% −0.70

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 6$41.7MACTU, IRD, CGTX, RNTX, LTRN
Q1 2026 6$52.9MACTU, IRD, CGTX, RNTX, LTRN
Q4 2025 6$82.6MACTU, CGTX, IRD, LTRN, RNTX
Q3 2025 6$88.9MACTU, CGTX, IRD, LTRN, RNTX
Q2 2025 6$72.6MACTU, IRD, LTRN, RNTX, CGTX
Q1 2025 6$79.2MACTU, LTRN, RNTX, CGTX, INAB
Q4 2024Amended 6$94.1MACTU, CGTX, RNTX, LTRN, INAB